Glassroth J, Jordan M, Wallace J M, Kvale P A, Follmann D A, Rosen M J, Reichman L B, Mossar M, Hopewell P C
Division of Pulmonary Medicine, Northwestern University Medical School, Chicago, IL.
Am J Prev Med. 1994 Sep-Oct;10(5):259-66.
Measures aimed at preventing complications and slowing progression of type-1 human immunodeficiency virus (HIV-1) can potentially reduce morbidity. Although little is known about the use of such measures, such data are critical for program planning. This study was performed to quantify the frequency and patterns of use for such interventions. We enrolled 1,171 persons infected with HIV, but without an acquired immunodeficiency syndrome (AIDS) defining diagnosis, in a multicenter prospective study of the pulmonary complications of HIV infection. Participants were homosexual/bisexual men, injection drug users (IDUs), or female sexual contacts of HIV-infected men. Centers were university-based and geographically dispersed across the United States. Standardized questionnaires were administered on entry and at three-month or six-month intervals; we correlated use of general and HIV-related preventive measures before entry and during the first three years in study with clinical/epidemiologic characteristics. Overall use of preventive interventions was low; only one third of study entrants had used such measures. Use was greatest among those with advanced HIV infection, but only half used preventive measures on entry; IDUs were less likely than homosexuals to use these services. Although use of interventions such as anti-Pneumocystis and antiretroviral agents increased during study participation, general measures such as pneumococcal vaccine and tuberculosis prophylaxis were used by less than 30% of those eligible for use. Among IDUs, cumulative use of these measures remained below 20% during the first three years of this study. We conclude that HIV-infected persons underuse preventive interventions, particularly general measures.(ABSTRACT TRUNCATED AT 250 WORDS)
旨在预防1型人类免疫缺陷病毒(HIV-1)并发症并减缓其进展的措施有可能降低发病率。尽管对于此类措施的使用情况了解甚少,但这些数据对于项目规划至关重要。本研究旨在量化此类干预措施的使用频率和模式。我们招募了1171名感染HIV但未确诊为获得性免疫缺陷综合征(AIDS)的患者,进行一项关于HIV感染肺部并发症的多中心前瞻性研究。参与者为男同性恋者/双性恋男性、注射吸毒者(IDU)或HIV感染男性的女性性伴侣。研究中心均以大学为基础,分布在美国各地。在入组时以及每隔三个月或六个月发放标准化问卷;我们将入组前及研究头三年期间一般及HIV相关预防措施的使用情况与临床/流行病学特征进行关联分析。预防性干预措施的总体使用率较低;只有三分之一的研究入组者使用过此类措施。在HIV感染晚期患者中使用率最高,但入组时只有一半的患者采取了预防措施;IDU使用这些服务的可能性低于同性恋者。尽管在研究期间抗肺孢子菌和抗逆转录病毒药物等干预措施的使用有所增加,但肺炎球菌疫苗和结核病预防等一般措施的使用比例不到符合使用条件者的30%。在IDU中,这些措施在本研究的头三年期间累计使用率仍低于20%。我们得出结论,HIV感染者对预防性干预措施使用不足,尤其是一般措施。(摘要截选至250字)